Myriad Genetics (NASDAQ:MYGN) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Myriad Genetics (NASDAQ:MYGN – Get Rating) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock.

Other research analysts also recently issued reports about the company. Stephens upped their price target on Myriad Genetics from $17.00 to $24.00 and gave the company an equal weight rating in a report on Monday, March 6th. Raymond James upped their price target on Myriad Genetics from $25.00 to $27.00 and gave the company an outperform rating in a report on Friday, March 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and a consensus target price of $26.20.

Myriad Genetics Stock Down 2.8 %

Shares of NASDAQ:MYGN opened at $23.08 on Thursday. Myriad Genetics has a 1 year low of $13.92 and a 1 year high of $28.18. The stock’s fifty day moving average price is $20.02 and its 200-day moving average price is $19.39.

Insider Buying and Selling at Myriad Genetics

In other Myriad Genetics news, CFO Richard Bryan Riggsbee sold 9,400 shares of the stock in a transaction dated Friday, January 20th. The stock was sold at an average price of $20.04, for a total value of $188,376.00. Following the transaction, the chief financial officer now owns 364,107 shares of the company’s stock, valued at $7,296,704.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders have sold 30,000 shares of company stock valued at $503,382. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MYGN. American Century Companies Inc. lifted its holdings in Myriad Genetics by 22.3% in the first quarter. American Century Companies Inc. now owns 16,607 shares of the company’s stock valued at $418,000 after acquiring an additional 3,027 shares during the period. US Bancorp DE lifted its holdings in Myriad Genetics by 14.6% in the first quarter. US Bancorp DE now owns 4,243 shares of the company’s stock valued at $108,000 after acquiring an additional 541 shares during the period. Natixis Advisors L.P. bought a new position in Myriad Genetics in the first quarter valued at about $372,000. Bank of Montreal Can lifted its holdings in Myriad Genetics by 147.9% in the first quarter. Bank of Montreal Can now owns 65,458 shares of the company’s stock valued at $1,687,000 after acquiring an additional 39,052 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in Myriad Genetics by 55.6% in the first quarter. MetLife Investment Management LLC now owns 42,669 shares of the company’s stock valued at $1,075,000 after acquiring an additional 15,255 shares during the period. Institutional investors own 99.08% of the company’s stock.

About Myriad Genetics

(Get Rating)

Myriad Genetics, Inc engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk of developing a disease later in life.